logo
logo

Hervolution Therapeutics Appoints Biotech Builder J. Robert Coleman As CEO To Accelerate Groundbreaking Immunotherapies To Treat Dark Genome Targets In Cancer, Aging, and Neurodegeneration

Dec 19, 2023over 1 year ago

Position

Chairman

Company

Hervolution Therapeutics

J. Robert Coleman
CopenhagenBiotechnology

Description

HERVOLUTION Therapeutics ApS , a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer.

Company Information

Company

Hervolution Therapeutics

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

HERVolution Therapeutics (formerly InProTher Aps) is a dark genome-focused biotechnology company based in Copenhagen, Denmark, and the U.S., pioneering novel human endogenous retrovirus (HERV)-targeted immunotherapies to address diseases of aging. With its proprietary engineering approaches, HERVolution has rationally redesigned HERV-antigens to yield a new class of highly immunogenic antigens to address cancer, metabolic, and other aging-related diseases. The company's world-class scientific team has advanced a strong product development pipeline, with lead program, IPT-001, anticipated to enter the clinic in 2025.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months